In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
10 Professionals Predict the Future of Clinical Trials
Discover what the future of clinical trials holds, according to ICON'S Senior Director of Business Development, Sarah Ikard, MBA as recorded by Xtalks in their interview with her at the recent DIA 2019 conference.
-
The long journey towards patient centricity
ICON’s Catherine Acquadro and Benoit Arnould discuss the evolution of patient reported outcomes over the last 30 years in this article on Patient Centricity from the July/August 2019 issue of Pharmafocus.
-
Adoptive Cell Transfer (ACT) Clinical Trials: The Long Road
ICON’s Martin Lachs and Brandon Fletcher provide expert commentary on Adoptive Cell Transfer (ACT) clinical trials in this July 2019 DDN News article.
-
Leveraging Novel Therapeutics & Diagnostic Assays
A European Biopharmaceutical Review article featuring expert insights from ICON company MolecularMD's Marissa Pearce on Leveraging Novel Therapeutics & Diagnostic Assays, presenting her argument that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.
This article has been taken from EBR - Summer 2019, Pages. 78-84. Samedan Ltd.
-
Technology the Key for Improving Trial Efficiencies & Retention
Past reliance on paper records made for a cumbersome, time-consuming process by making data management highly complex. However, many of the biggest issues remain — in particular, recruitment and retention of patients. Most pharmaceutical companies and contract research organisations have adopted technology solutions, including electronic data capture solutions and clinical trial management systems to increase efficiencies, reduce costs, and improve the patient experience. These solutions have been instrumental in improving clinical trial processes. Read this PharmaVOICE article to learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.
-
Oncology & ASCO 2019: Moving from Autologous to Allogeneic ACT Paradigms
We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). ACT approaches have the possibilities of therapies with reduced safety concerns, a higher therapeutic index, as well as breadth of targets including solid tumours. Learn more in our recent Pharmaphorum article.
-
Increasing Predictability in Patient Recruitment
In this recent PharmaVOICE article, ICON expert E.B. McLindon explores the increasing complexity of protocol design, emphasizing the importance of assessing the burden on both the patient and site when evaluating the potential impact on patient recruitment.
-
The Perverse Incentive: A Unified Approach to Patient Engagement
In operationalising a clinical trial, there are an increasing number of patient facing technologies to aid data collection, enable patient support and improve retention and compliance, with the potential to benefit patients and sponsors alike. Learn more in this recent International Clinical Trials (ICT) article on the need for a unified approach to patient engagement.
-
ICON Acquires MeDiNova Research Site in Europe & Africa
This recent Applied Clinical Trials article discusses ICON's acquisition of majority shareholding in MeDiNova Research, a site network with research sites in Europe and Africa, granting our company the right to acquire the remaining shares in the company by the third quarter of 2020. MeDiNova Research currently has a network of 33 active clinical research sites in the UK, Spain, South Africa, Poland and Romania.
-
The Digital Trial: How Technology Is Changing Trial Design, Start-Up And Close-Out
The constant data stream from patients’ mobile devices and sensors generate large datasets that are difficult to analyze manually—just one motion sensor gathering data from a few dozen patients creates nearly one billion data points per day (ICON). To understand these large datasets, AI and machine learning are necessary to automate analyses. Incorporating this technology can lead to faster and more transparent access to data. In addition, it can help sponsors collect the right data to support submission and filing for regulatory review, and, in the end, speed a product’s path to approval and reduce time to market. In this Clinical Informatics News article, featuring commentary from ICON expert Marie McCarthy, leveraging technology to accelerate study close-out is further discussed.
